V. Gimenez

Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T

K. Gelmon, J. Baselga, M. Climent, 2007 .

An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)

C. Parker, J. Bono, C. Sternberg, 2005 .

Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

B. Lum, C. Ng, S. Kelsey, 2006, Pharmaceutical Research.